Thermo Fisher Scientific to invest $2 billion to expand US operation
Investment demonstrates confidence in America’s commitment to science and innovation
Investment demonstrates confidence in America’s commitment to science and innovation
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Subscribe To Our Newsletter & Stay Updated